Improving antiplatelet therapy for atherothrombotic disease: Preclinical and clinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1

Hamostaseologie

Volumn 29, Issue 4, 2009, Pages 349-355

  Hildemann, Steven K ^a   Bode, C ^b  

^a Essex Pharma GmbH   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Antiplatelet therapy; Atherothrombosis; PAR 1; SCH 530348; Thrombin receptor antagonist

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; HEPARIN; HIRULOG; PLACEBO; PROTEINASE ACTIVATED RECEPTOR 1; RECEPTOR BLOCKING AGENT; SCH 205831; SCH 602539; THROMBIN; TICLOPIDINE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; HUMAN; ISCHEMIA; LOADING DRUG DOSE; NONHUMAN; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

EID: 70549108948     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617133     Document Type: Review

References (33)

1. Allender S, Scarborough P, Peto V et al. European cardiovascular disease statistics. http://www.ehn heart.org/content/Section-Intro.asp?level0= 1457&docid=4345 (April 15, 2009).
2. Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics - 2009 Update. Circulation 2009; 119: e21-e181.
3. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
4. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007; 100: 1261-1275.
5. Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-1621.
6. Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-1189. (Pubitemid 40397259)
7. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015. (Pubitemid 350106708)
8. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502. (Pubitemid 32758501)
9. Peters RJ, Mehta SR, Fox KA et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108: 1682-1687.
10. Brummel KE, Paradis SG, Butenas S et al. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 148-152.
11. Mann KG. Thrombin formation. Chest 2003; 124: 4S-10S.
12. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006; 99: 1293-1304.
13. Cook JJ, Sitko GR, Bednar B et al. An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation 1995; 91: 2961-2971.
14. Derian CK, Damiano BP, Addo MF et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 2003; 304: 855-861.
15. Kato Y, Kita Y, Hirasawa-Taniyama Y et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol 2003; 473: 163-169. (Pubitemid 36929880)
16. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800-1814.
17. Vandendries ER, Hamilton JR, Coughlin SR et al. Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci USA 2007; 104: 288-292.
18. Chintala MS, Chiu PJ, Bernadino V et al. Disparate effects of thrombin receptor activating peptide on platelets and peripheral vasculature in rats. Eur J Pharmacol 1998; 349: 237-243. (Pubitemid 28277093)
19. Chintala M, Ahn HS, Foster C et al. Antithrombotic effects of SCH 205831: a potent, selective and orally active antagonist of the PAR-1 thrombin receptor. J Thromb. Haemost 2005; 3(suppl1): OR286.
20. Chintala M, Kurowski S, Vemulapalli S et al. Efficacy of SCH 602539, a selective thrombin receptor antagonist alone and in combination with cangrelor in a Folts model of thrombosis in anesthetized monkeys. Eur Heart J 2007; 28 (suppl1): 188.
21. Chackalamannil S, Wang Y, Greenlee WJ et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008; 51: 3061-3064. (Pubitemid 351821864)
22. Chintala M, Vemulapalli S, Kurowski S et al. SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys. Arterioscl Thromb Vasc Biol 2008; 28: e138-e139, P579.
23. Kosoglou T, Tiessen R, Van Vliet AA et al. Safety and tolerability of SCH 530348, a novel antiplatelet agent, after single and multiple oral dosing in healthy subjects. Eur Heart J 2008; 29 (Suppl): 201, P1340.
24. Reyderman L, Kosoglou T, Kasserra C et al. Lack of ethnic differences in the pharmacodynamics (PD) and pharmacokinetics (PK) of SCH 530348, a novel oral antiplatelet agent, in Japanese and Caucasian subjects. Clin Pharmacol Ther 2009; 85 (Suppl 1): S21, PI-41.
25. Reyderman L, Kosoglou T, Tiessen R et al. Pharmacokinetics of SCH 530348, a novel antiplatelet agent, after single and multiple oral dosing in healthy subjects. Am Assoc of Pharmaceut Sci J 2008; 10 (S2): 942.
26. Kosoglou T, Reyderman L, Tiessen R et al. TRAP-induced platelet aggregation following single and multiple rising oral doses of SCH 530348, a novel thrombin receptor antagonist, in healthy volunteers. Clin Pharmacol Ther 2009; 85 (S1): S21, PI-40.
27. Becker RC, Moliterno DJ, Jennings LK et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009; 373: 919-928.
28. Jennings LK, Earhart A, Becker RC et al. Thrombin receptor antagonist (TRA; SCH 530348) is a selective, potent inhibitor of PAR1 activity with predictable pharmacokinetics. Circulation 2007; 116 (suppl): , 3010.
29. Goto S, Yamaguchi T, Ikeda Y et al. Phase II trial of the novel antiplatelet agent, SCH 530348, in Japanese patients with non-ST segment elevation acute coronary syndromes (NSTE ACS). Eur Heart J 2008; 29 (Suppl): 829, P4767.
30. Shinohara Y, Goto S, Shimizu K et al. A phase II safety study of novel antiplatelet agent, SCH 530348, in Japanese patients with prior ischemic stroke. Int J Stroke 2008; 3 (Suppl 1): 139, PO101-193.
31. Trial to assess the effects of SCH 530348 in preventing heart attack and stroke in patients with acute coronary syndrome (TRACER; study P04736AM1, NCT00527943). http://www.clinicaltrials.gov/ct2/show/NCT00527943?term= SCH+530348&rank=2&flds=Xabef.
32. Trial to assess the effects of SCH 530348 in preventing heart attack and stroke in patients with atherosclerosis (TRA 2°P - TIMI 50; study P04737, NCT00526474). http://www.clinicaltrials.gov/ct2/show/NCT00526474?term= SCH+530348&rank=4&flds=Xabef.
33. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-264.